Browsing Internal Medicine by Subject "Treatment"

Browsing Internal Medicine by Subject "Treatment"

Sort by: Order: Results:

  • Case study : a novel use for faecal microbial transplantation 
    Ueckermann, Veronica; Francis, E.W. (NISC (Pty) Ltd, Medpharm Publications, and Informa UK Limited, 2019)
    Faecal microbiota transplantation (FMT) refers to the infusion of faeces from a healthy donor, into the gastrointestinal tract of a recipient patient. There is considerable evidence for the efficacy of FMT for the ...
  • The COVID-19 treatment landscape : a South African perspective on a race against time 
    Hendricks, Candice Laverne; Herd, Candice Lee; Nel, Marcel; Tintinger, Gregory Ronald; Pepper, Michael Sean (Frontiers Media, 2021-02-19)
    The pandemic caused by SARS-CoV-2 has infected more than 94 million people worldwide (as of 17 January 2020). Severe disease is believed to be secondary to the cytokine release syndrome (CRS or “cytokine storm”) which ...
  • Diagnosis and treatment of diabetic ketoacidosis 
    Van Zyl, Danie G. (Medpharm Publishers, 2008-01)
    Diabetic ketoacidosis (DKA) is the most frequent hyperglycaemic acute diabetic complication. Furthermore it carries a significant risk of death, which can be prevented by early and effective management. All physicians, ...
  • Diffuse infiltrative lymphocytosis syndrome (DILS) 
    Levay, Peter Ferenc; Botes, M.E. (Medpharm Publications, 2008-03)
    Diffuse infiltrative lymphocytosis syndrome (DILS) is characterised by a persistent CD8+ lymphocytosis and lymphocytic infiltration of various organs. The reported prevalence varies between 0.85 – 3%, and appears to be ...
  • Elucidating the antimicrobial mechanisms of colistin sulfate on Mycobacterium tuberculosis using metabolomics 
    Koen, Nadia; Van Breda, Shane Vontelin; Loots, Du Toit (Elsevier, 2018-07)
    Considering the disadvantageous of first line anti-tuberculosis (TB) drugs, including poor patient adherence, drug side effects, the long treatment duration and rapidly increasing microbe resistance, alternative treatment ...
  • Human immunodeficiency virus infection and inflammatory arthritis : a review of clinical and imaging features 
    Suleman, Farhana Ebrahim; Ally, Mahmood Moosa Tar Mahomed (AOSIS OpenJournals, 2017-11-14)
    The reported prevalence of articular manifestations of human immunodeficiency virus (HIV) varies, but with sub-Saharan Africa accounting for almost 70% of the people living with HIV, this results in a considerable burden ...
  • Hypercholesterolaemia and coronary risk 
    Ker, James A. (New Media Publishing, 2016-05)
    Studies have shown that only 10.6% of people with hypercholesterolaemia receive a statin or treatment. There is a within-person variability of cholesterol measurements and therefore a one-time measurement of cholesterol ...
  • Impact of FDG PET on the management of TBC treatment 
    Sathekge, Mike Machaba; Maes, Alex; Kgomo, Mbo; Stoltz, Anton Carel; Pottel, Hans; Van de Wiele, Christophe (Schattauer, 2010)
    The AIM: of this study is to assess the potential impact of double-phase FDG PET versus routine staging in HIV-negative patients suffering from tuberculosis. PATIENTS, METHODS: 16 consecutive patients suffering from ...
  • LDL-cholesterol reduction vs LDL target level : which is more important? 
    Ker, James A. (New Media Publishing, 2016-07)
    There is enough documented evidence of the role of low-density-lipoprotein cholesterol (LDL-C) in the pathogenesis of atherosclerotic cardiovascular disease (CVD).
  • Metabolomics of colistin methanesulfonate treated Mycobacterium tuberculosis 
    Koen, Nadia; Van Breda, Shane Vontelin; Loots, Du Toit (Elsevier, 2018-07)
    Over the past 5 years, there has been a renewed interest in finding new compounds with anti-TB action. Colistin methanesulfonate or polymyxin E, is a possible anti-TB drug candidate, which may in future be used either alone ...
  • Thrombotic complications 
    Ker, James A. (New Media Publishing, 2015-09)
    There have been significant advances in the treatment of heart failure (HF) with a reduction in mortality. Despite this improvement in mortality, HF still has a bad prognosis and research is ongoing to find ways to improve ...
  • The treatment of cholesterol : issues, effects and targets 
    Ker, James A. (South African Academy of Family Practice/Primary Care, 2010-11)
    Statins are the most powerful cholesterol lowering drugs currently available. Statins inhibit 3-hydroxy-3-methylglutaryl-coenzyme A (HMG CoA) reductase, which leads to reduced cholesterol synthesis. In addition, low-density ...